{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:16:10Z","timestamp":1790907370582,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T00:00:00Z","timestamp":1259020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1038\/sj.bjc.6605428","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T23:59:05Z","timestamp":1259107145000},"page":"1817-1823","source":"Crossref","is-referenced-by-count":42,"title":["CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients"],"prefix":"10.1038","volume":"101","author":[{"given":"H","family":"Jernstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"B\u00e5geman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P-E","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ingvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,24]]},"reference":[{"key":"BF6605428_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/jcp.53.11.846","volume":"53","author":"R Arisio","year":"2000","unstructured":"Arisio R, Sapino A, Cassoni P, Accinelli G, Cuccorese MC, Mano MP, Bussolati G (2000) What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas? J Clin Pathol 53: 846\u2013850","journal-title":"J Clin Pathol"},{"key":"BF6605428_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64: 1579\u20131589","journal-title":"Biochem Pharmacol"},{"key":"BF6605428_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399403005842","volume":"5","author":"O Belton","year":"2003","unstructured":"Belton O, Fitzgerald DJ (2003) Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med 5: 1\u201318","journal-title":"Expert Rev Mol Med"},{"key":"BF6605428_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1179\/joc.2006.18.4.421","volume":"18","author":"MC Boruban","year":"2006","unstructured":"Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A (2006) Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 18: 421\u2013424","journal-title":"J Chemother"},{"key":"BF6605428_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/02841860300672","volume":"42","author":"G Chebil","year":"2003","unstructured":"Chebil G, Bendahl PO, Ferno M (2003) Estrogen and progesterone receptor assay in paraffin-embedded breast cancer\u2014reproducibility of assessment. Acta Oncol 42: 43\u201347","journal-title":"Acta Oncol"},{"key":"BF6605428_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11: 597\u2013607","journal-title":"Pharmacogenetics"},{"key":"BF6605428_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-007-9645-1","volume":"109","author":"L Dihge","year":"2008","unstructured":"Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M (2008) Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109: 255\u2013262","journal-title":"Breast Cancer Res Treat"},{"key":"BF6605428_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00228-008-0508-4","volume":"64","author":"P Dorado","year":"2008","unstructured":"Dorado P, Cavaco I, Caceres MC, Piedade R, Ribeiro V, Llerena A (2008) Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 64: 967\u2013970","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6605428_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early breast cancer trialists' collaborative group","year":"2005","unstructured":"Early breast cancer trialists' collaborative group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687\u20131717","journal-title":"Lancet"},{"key":"BF6605428_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403\u2013410","journal-title":"Histopathology"},{"key":"BF6605428_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45\u201353","journal-title":"Lancet Oncol"},{"key":"BF6605428_CR12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/jnci\/djm059","volume":"99","author":"AG Glass","year":"2007","unstructured":"Glass AG, Lacey Jr JV, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980\u20132006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152\u20131161","journal-title":"J Natl Cancer Inst"},{"key":"BF6605428_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","volume":"83","author":"MP Goetz","year":"2008","unstructured":"Goetz MP, Kamal A, Ames MM (2008) Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83: 160\u2013166","journal-title":"Clin Pharmacol Ther"},{"key":"BF6605428_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133\u20131144","journal-title":"Ann Oncol"},{"key":"BF6605428_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00228-003-0590-6","volume":"59","author":"L Griskevicius","year":"2003","unstructured":"Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML (2003) Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 59: 103\u2013109","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6605428_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496\u2013526","journal-title":"Pharmacol Ther"},{"key":"BF6605428_CR17","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1158\/0008-5472.CAN-06-3643","volume":"67","author":"JG Jiang","year":"2007","unstructured":"Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC, Wang DW (2007) Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 67: 6665\u20136674","journal-title":"Cancer Res"},{"key":"BF6605428_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"BF6605428_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/00008571-200412000-00004","volume":"14","author":"BP King","year":"2004","unstructured":"King BP, Khan TI, Aithal GP, Kamali F, Daly AK (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14: 813\u2013822","journal-title":"Pharmacogenetics"},{"key":"BF6605428_CR20","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2001.19.7.2010","volume":"19","author":"P Malmstr\u00f6m","year":"2001","unstructured":"Malmstr\u00f6m P, Bendahl PO, Boiesen P, Br\u00fcnner N, Idvall I, Fern\u00f6 M, South Sweden Breast Cancer Group (2001) S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19: 2010\u20132019","journal-title":"J Clin Oncol"},{"key":"BF6605428_CR21","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0959-8049(03)00324-1","volume":"39","author":"P Malmstr\u00f6m","year":"2003","unstructured":"Malmstr\u00f6m P, Holmberg L, Anderson H, Mattsson J, J\u00f6nsson PE, Tennvall-Nittby L, Balldin G, Loven L, Svensson JH, Ingvar C, M\u00f6ller T, Holmberg E, Wallgren A, Swedish Breast Cancer Group (2003) Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 39: 1690\u20131697","journal-title":"Eur J Cancer"},{"key":"BF6605428_CR22","doi-asserted-by":"publisher","first-page":"H215","DOI":"10.1152\/ajpheart.01118.2001","volume":"284","author":"M Medhora","year":"2003","unstructured":"Medhora M, Daniels J, Mundey K, Fisslthaler B, Busse R, Jacobs ER, Harder DR (2003) Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284: H215\u2013H224","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BF6605428_CR23","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1242\/jcs.02674","volume":"118","author":"UR Michaelis","year":"2005","unstructured":"Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118: 5489\u20135498","journal-title":"J Cell Sci"},{"key":"BF6605428_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1096\/fj.02-0640fje","volume":"17","author":"UR Michaelis","year":"2003","unstructured":"Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, Busse R (2003) Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17: 770\u2013772","journal-title":"FASEB J"},{"key":"BF6605428_CR25","unstructured":"NCBI SNP homepage (2008) NCBI SNP homepage Access date 2008-07-15 \n                    http:\/\/www.ncbi.nlm.nih.gov\/SNP\/snp_ref.cgi?rs=1058930"},{"key":"BF6605428_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1124\/dmd.32.5.484","volume":"32","author":"M Sandberg","year":"2004","unstructured":"Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32: 484\u2013489","journal-title":"Drug Metab Dispos"},{"key":"BF6605428_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","volume":"25","author":"W Schroth","year":"2007","unstructured":"Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25: 5187\u20135193","journal-title":"J Clin Oncol"},{"key":"BF6605428_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45: 68\u201378","journal-title":"J Clin Pharmacol"},{"key":"BF6605428_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","volume":"254","author":"U Yasar","year":"1999","unstructured":"Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254: 628\u2013631","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6605428_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","volume":"299","author":"U Yasar","year":"2002","unstructured":"Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299: 25\u201328","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6605428_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1006\/abbi.1995.1438","volume":"322","author":"DC Zeldin","year":"1995","unstructured":"Zeldin DC, DuBois RN, Falck JR, Capdevila JH (1995) Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322: 76\u201386","journal-title":"Arch Biochem Biophys"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605428","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:42:55Z","timestamp":1684413775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,24]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["BF6605428"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605428","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,24]]}}}